Viracta Therapeutics, Inc. (VIRX) Tops Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Viracta Therapeutics (VIRX) PT Lowered to $4 at RBC Capital
August 15, 2024 6:16 AM EDTRBC Capital analyst Kennen MacKay lowered the price target on Viracta Therapeutics (NASDAQ: VIRX) to $4.00 (from $6.00) while maintaining a Outperform rating.
The analyst comments "VIRX shared new NAVAL-1 data (Stage 1+2) that suggest stronger efficacy of Nana-val in 2L EBV+ PTCL (vs. 2L+,... More
